Small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR) in the PARATHYROID GLANDS and other tissues. They lower the threshold for CaSR activation by extracellular calcium ions and diminish PARATHYROID HORMONE (PTH) release from parathyroid cells.
Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.
Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.
A class of G-protein-coupled receptors that react to varying extracellular CALCIUM levels. Calcium-sensing receptors in the PARATHYROID GLANDS play an important role in the maintenance of calcium HOMEOSTASIS by regulating the release of PARATHYROID HORMONE. They differ from INTRACELLULAR CALCIUM-SENSING PROTEINS which sense intracellular calcium levels.
Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.
A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)
A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.
Excision of one or more of the parathyroid glands.
A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
Abnormally high level of calcium in the blood.
A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.
Excision of kidney.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.
Inorganic salts of phosphoric acid.
Personal names, given or surname, as cultural characteristics, as ethnological or religious patterns, as indications of the geographic distribution of families and inbreeding, etc. Analysis of isonymy, the quality of having the same or similar names, is useful in the study of population genetics. NAMES is used also for the history of names or name changes of corporate bodies, such as medical societies, universities, hospitals, government agencies, etc.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
Services providing pharmaceutic and therapeutic drug information and consultation.
An agency of the NATIONAL INSTITUTES OF HEALTH concerned with overall planning, promoting, and administering programs pertaining to advancement of medical and related sciences. Major activities of this institute include the collection, dissemination, and exchange of information important to the progress of medicine and health, research in medical informatics and support for medical library development.
Excretion of abnormally high level of CALCIUM in the URINE, greater than 4 mg/kg/day.
Disorders in the processing of calcium in the body: its absorption, transport, storage, and utilization.
A condition characterized by calcification of the renal tissue itself. It is usually seen in distal RENAL TUBULAR ACIDOSIS with calcium deposition in the DISTAL KIDNEY TUBULES and the surrounding interstitium. Nephrocalcinosis causes RENAL INSUFFICIENCY.
A non-electrogenic sodium-dependent phosphate transporter. It is found primarily in apical membranes of PROXIMAL RENAL TUBULES.
Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.
Formation of stones in the KIDNEY.
A hereditary disorder characterized by HYPOPHOSPHATEMIA; RICKETS; OSTEOMALACIA; renal defects in phosphate reabsorption and vitamin D metabolism; and growth retardation. Autosomal and X-linked dominant and recessive variants have been reported.
A non-neoplastic inflammatory lesion, usually of the jaw or gingiva, containing large, multinucleated cells. It includes reparative giant cell granuloma. Peripheral giant cell granuloma refers to the gingiva (giant cell epulis); central refers to the jaw.
Disorders caused by interruption of BONE MINERALIZATION manifesting as OSTEOMALACIA in adults and characteristic deformities in infancy and childhood due to disturbances in normal BONE FORMATION. The mineralization process may be interrupted by disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis, resulting from dietary deficiencies, or acquired, or inherited metabolic, or hormonal disturbances.
FIBROUS DYSPLASIA OF BONE involving only one bone.
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.
Native, inorganic or fossilized organic substances having a definite chemical composition and formed by inorganic reactions. They may occur as individual crystals or may be disseminated in some other mineral or rock. (Grant & Hackh's Chemical Dictionary, 5th ed; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Health facilities providing therapy and/or rehabilitation for substance-dependent individuals. Methadone distribution centers are included.
Disorders related to substance abuse.
A specialized residential treatment program for behavior disorders including substance abuse. It may include therapeutically planned group living and learning situations including teaching of adaptive skills to help patient functioning in the community. (From Kahn, A. P. and Fawcett, J. Encyclopedia of Mental Health, 1993, p320.)
Disorders in the processing of phosphorus in the body: its absorption, transport, storage, and utilization.
An application that must be submitted to a regulatory agency (the FDA in the United States) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured. (From the "New Medicines in Development" Series produced by the Pharmaceutical Manufacturers Association and published irregularly.)
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
The deliberate and methodical practice of finding new applications for existing drugs.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
Laws concerned with manufacturing, dispensing, and marketing of drugs.
Any device or element which converts an input signal into an output signal of a different form. Examples include the microphone, phonographic pickup, loudspeaker, barometer, photoelectric cell, automobile horn, doorbell, and underwater sound transducer. (McGraw Hill Dictionary of Scientific and Technical Terms, 4th ed)

Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet. (1/36)

INTRODUCTION: The most common cause of hypercalcemia in patients with transplanted kidneys is persistent hyperparathyroidism, which presents in 10%-30% of patients with functioning renal grafts. In these patients, the treatment of vitamin D-resistant hyperparathyroidism traditionally required parathyroidectomy. Calcimimetic agents represent a new therapeutic alternative; they inhibit parathyroid hormone (PTH) secretion, increasing the sensitivity of the calcium-sensitive receptor in the parathyroid gland. The objective of this study is to evaluate the efficacy of cinacalcet in renal transplant patients with persistent hyperparathyroidism. METHODS: Cinacalcet 30 mg/day was prescribed to 17 renal transplant patients (6 women, 11 men) with a mean age of 49 years and hypercalcemia secondary to persistent hyperparathyroidism. The treatment started 58.17 +/- 35.16 months posttransplant, with 1 year of follow-up. RESULTS: Calcium in serum fell from 10.5 +/- 0.74 to 9.4 +/- 0.84 mg/dL (p<0.001), whereas phosphorous levels were not significantly altered. The fall in PTH was from 204.79 +/- 78 to 148.55 +/- 56 pg/mL (p<0.011). Kidney function remained stable, and immunosuppressant drug levels remained unchanged. The dose of cinacalcet was increased to 60 mg in 2 patients. No significant adverse effects were described, and none of the patients had to suspend the treatment. CONCLUSIONS: Calcimimetic agents represent a therapeutic alternative in transplant patients with persistent hyperparathyroidism, as they correct hypercalcemia and reduce PTH levels with no adverse effects on kidney function. Prospective, controlled studies should be designed to evaluate the long-term effects and evolution after suspension of the treatment.  (+info)

Vascular actions of calcimimetics: role of Ca(2)(+) -sensing receptors versus Ca(2)(+) influx through L-type Ca(2)(+) channels. (2/36)

 (+info)

Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. (3/36)

 (+info)

The calcium-sensing receptor and calcimimetics in blood pressure modulation. (4/36)

 (+info)

Functional expression of the extracellular calcium sensing receptor (CaSR) in equine umbilical cord matrix size-sieved stem cells. (5/36)

 (+info)

Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. (6/36)

 (+info)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. (7/36)

 (+info)

Regression of vascular calcification in a patient treated with cinacalcet: a case report. (8/36)

 (+info)

Background: Autoclaving rodent diets is common in laboratory animals, but autoclaving increases the formation of dietary advanced glycation end-products (AGE). We studied the effect of autoclaved (AC) diet alone or in combination with a diet high in bioavailable phosphorus on biochemistries of chronic kidney disease-mineral and bone disorder (CKD-MBD), intestinal gene expression, and oxidative stress. Methods: Male CKD rats (Cy/+) and normal littermates were fed 1 of 3 diets: AC 0.7% phosphorus grain-based diet for 28 weeks (AC); AC diet for 17 weeks followed by non-autoclaved (Non-AC) 0.7% phosphorus casein diet until 28 weeks (AC + Casein); or Non-AC diet for 16 weeks followed by a Non-AC purified diet until 30 weeks (Non-AC + Casein). Results: AC diets contained ~3× higher AGEs and levels varied depending on the location within the autoclave. Rats fed the AC and AC + Casein diets had higher total AGEs and oxidative stress, irrespective of kidney function. Kidney function was more severely
Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism.
We demonstrate that systemic activation of the CaR with the type-II calcimimetic, cinacalcet, at doses producing physiologically relevant reductions in blood iCa2+ and PTH acutely increases blood pressure in both anesthetized uremic and nonuremic rats. The increase in blood pressure was mediated by vasoconstriction as evidenced by increases in resistance in vascular beds perfused by the carotid, mesenteric, and hindlimb systemic arteries. Acute increases in blood pressure produced by i.v. infusion of cinacalcet in anesthetized rats were similar to those produced by another type-II calcimimetic, R-568, administered s.c. in conscious telemetry-instrumented rats (Odenwald et al., 2006), thus, acute increases in blood pressure may represent a class effect of calcimimetic agents in the rat.. Although, in previous studies, the mechanism responsible for acute increases in blood pressure produced by CaR activation with R-568 was not fully characterized, Odenwald et al. (2006) hypothesized that R-568 ...
Cinacalcet with NDC 47335-380 is a a human prescription drug product labeled by Sun Pharmaceutical Industries, Inc.. The generic name of Cinacalcet is cinacalcet.
Cinacalcet with NDC 68180-226 is a a human prescription drug product labeled by Lupin Pharmaceuticals, Inc.. The generic name of Cinacalcet is cinacalcet.
A Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens are Used in Subjects with Secondary Hyperparathyroidism of End-stage Renal Disease (ESRD). ...
With my PTH level over 80, I have started Cinacalcet 30mg today, so it will be interesting to see what happens to my PTH level and Calcium level. Interestingly
Sprawdź ile zapłacisz za lek Cinacalcet Hydrochloride w aptece, znajdź tańsze zamienniki leku. Określ swoje uprawnienia i sprawdź jakie zniżki Ci przysługują.
Easy-to-read patient leaflet for Cinacalcet. Includes indications, proper use, special instructions, precautions, and possible side effects.
A new definition and classification of chronic kidney disease-mineral and bone disorder (CKD-MBD) was proposed in 2005 and it was later followed by a guideline publication on this topic from Kidney Disease: Improving Global Outcomes (KDIGO) in 2009. This work recognized that CKD-MBD is a syndrome of bone abnormalities, laboratory abnormalities, and vascular calcification linked to fractures, cardiovascular disease, and mortality. Because of limited data at the time of the original guideline systematic review, many of the recommendations were cautiously vague. KDIGO convened a Controversies Conference in October 2013 to review the CKD-MBD literature published since the 2009 guideline. Specifically, the objective of this conference was to determine whether sufficient new data had emerged to support a reassessment of the CKD-MBD guideline and if so to determine the scope of these potential revisions. This report summarizes the results of these proceedings, highlighting important new studies conducted in
In this randomized, placebo controlled trial, patients on hemodialysis with moderate-to-severe secondary hyperparathyroidism were randomized to receive either cinacalcet or placebo. No difference was seen in the primary composite end point (time until death, myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event) between cinacalcet (48.2%) versus placebo (49.2%) HR 0.93; 95% CI, 0.85 to 1.02; P=0.11. Hypocalcemia and gastrointestinal adverse events were more common in patients on active treatment.. See the accompanying editorial ...
The 1K1C model is a severe, acute model of renal dysfunction which enables the activity of AMG 416 and cinacalcet to be investigated in the presence of the highly elevated levels of PTH and lack of kidney function typically seen in CKD-MBD patients receiving hemodialysis [1]. Due to its acute nature, the 1K1C model is not associated with the parathyroid gland hyperplasia seen in the rat 5/6 Nx uremic model and in dialysis patients with SHPT [9, 10]. However, it is an excellent model for assessing PTH-lowering activity in the background of severe kidney dysfunction. In this study, plasma PTH levels were significantly reduced by a single dose of either AMG 416 or cinacalcet. The effect of cinacalcet on PTH was of a lesser extent and shorter duration than seen with AMG 416, which maintained PTH lowering for more than 24 hr. The prolonged suppression of plasma PTH in the 1K1C model by AMG 416 is consistent with the pharmacokinetics (PK) observed for AMG 416 in normal rats and in different uremic ...
The aim of this study is to compare the effectiveness of etelcalcetide and cinacalcet in the management of secondary hyperparathyroidism in haemodialysis
In an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of death or major cardiovascular events in patients with moderate-to-severe secondary hyperparathyroidism who were undergoing dialysis. (Funded by Amgen; EVOLVE ClinicalTrials.gov number, NCT00345839.).
KDIGO Issues Updated Guidelines for Treatment of CKD-MBD In late June, the Kidney Disease Improving Global Outcomes (KDIGO) updated its Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). The update amends the 2009 KDIGO Clinical Practice Guideline and includes revised positions on standards of care for the treatment of secondary hyperparathyroidism ... Read More ». ...
A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (also known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients with Secondary ...
CINACALCET (sin a CAL set) is used to treat patients with chronic kidney disease who are on dialysis. It is also used to treat high levels of calcium in the blood of patients with certain parathyroid gland problems.
Search for Cinacalcet Manufacturers / Generic Brands / Substitute / alternatives, prices, m.r.p. Order Medicines online on PillsBills.com. Free shipping all over India.
Background. Cinacalcet, a calcimimetic agent, is effective in treating both primary and secondary hyperparathyroidism. Because hyperparathyroidism induces mineralized bone loss, we investigated the effects of cinacalcet treatment on bone mineral density (BMD) in patients with secondary hyperparathyroidism due to chronic kidney disease.. Methods. Ten patients who were receiving haemodialysis and four patients, who had stage 4 chronic kidney disease participated and completed the multicentre, randomized, double-blind, placebo-controlled trials evaluating the safety and efficacy of cinacalcet for treating secondary hyperparathyroidism. The efficacy of cinacalcet was assessed by plasma intact parathyroid hormone (iPTH) levels. A dual energy X-ray absorptiometry was performed to measure the BMD of total proximal femurs and lumbar spine (L2-L4) before and after 26 weeks of treatment.. Results. Cinacalcet reduced iPTH from 912±296 to 515±359 pg/ml in haemodialysis patients and from 210±46 to 56±51 ...
Ongoing studies are attempting to determine the optimal combination of calcimimetics and calcitriol analogs for the treatment of SHPT. The ACHIEVE study recently compared the effects of Cinacalcet plus fixed low-dose calcitriol analogs with flexible doses of calcitriol analogs on PTH, Ca, and P levels (25). In this study, we used samples from ACHIEVE to perform a per-protocol analysis of the effects of treatment on FGF23, a factor associated with poor outcomes in ESRD (15). We found that the treatment regimen using Cinacalcet plus fixed low-dose calcitriol analogs results in a relative decrease in FGF23 levels compared with an approach using escalating doses of calcitriol analogs alone. This study is the first report of the disparate effects of different treatment strategies on FGF23 levels in HD patients.. The existence of complex interactions between treatment agents and mineral metabolic parameters make it difficult to ascribe the observed differences in FGF23 to a specific therapeutic ...
Three 6-month, multicenter, randomized, double-blind, placebo-controlled clinical studies of similar design were conducted in patients with CKD on dialysis. A total of 665 patients were randomized to cinacalcet and 471 patients to placebo. The mean age of the patients was 54 years, 62% were male, and 52% were Caucasian. The average baseline iPTH level by the Nichols IRMA was 712 pg/mL, with 26% of the patients having a baseline iPTH level , 800 pg/mL. The mean baseline Ca x P product was 61 mg2/dL2. The average duration of dialysis prior to study enrollment was 67 months. Ninety-six percent of patients were on hemodialysis and 4% on peritoneal dialysis. At study entry, 66% of the patients were receiving vitamin D sterols and 93% were receiving phosphate binders. Cinacalcet (or placebo) was initiated at a dose of 30 mg once daily and titrated every 3 or 4 weeks to a maximum dose of 180 mg once daily to achieve an iPTH of ≤ 250 pg/mL. The dose was not increased if a patient had any of the ...
BACKGROUND: In kidney transplant recipients, persistent hyperparathyroidism leads to hypercalcemia and increased urinary phosphorus excretion. The calcimimetic drug cinacalcet effectively decreases parathyroid hormone (PTH) levels and corrects hypercalcemia in these patients. The purpose of the present study is to examine the effect of cinacalcet treatment on determinants of renal phosphorus reabsorption under steady-state conditions. STUDY DESIGN: Open-label prospective uncontrolled trial. SETTING & PARTICIPANTS: 10 stable kidney transplant recipients with persistent hyperparathyroidism. INTERVENTION: Cinacalcet, 30 and 60 mg/d, for 2 weeks. OUTCOMES & MEASURES: Changes in urinary phosphorus excretion in timed urine samples, intact and carboxy-terminal (C-term) fibroblast growth factor 23 (FGF-23), intact PTH, venous pH, and bicarbonate values at defined intervals over 24 hours. RESULTS: Cinacalcet decreased renal phosphorus excretion in the first 8 hours by 30% to 40%, but not from 8 to 24 ...
The one-year mortality rate is consistently higher among PD patients than HD patients in Singapore; this may be due to the higher prevalence of significant comorbidities (e.g. ischaemic heart disease, cerebrovascular disease and peripheral vascular disease) among incident PD patients.(7) Studies have found that abnormal CKD-MBD parameters can affect all-cause mortality among patients on dialysis.(3-5,14,15) CKD-MBD is characterised by either one or a combination of the following items: (a) abnormalities in serum calcium, phosphorus or i-PTH levels, or vitamin D metabolism; (b) abnormalities in bone turnover, mineralisation, volume, linear growth or strength; and (c) the presence of vascular or other soft-tissue calcifications.(12) The complex relationship between abnormal CKD-MBD parameters and adverse clinical outcomes among incident PD patients has not been explored. Therefore, the present study was conducted to determine the prevalence of CKD-MBD among incident PD patients and examine the ...
Abnormalities in bone and mineral metabolism, encompassed by the term chronic kidney disease - mineral and bone disorder (CKD-MBD) [ 1 ], play a …
Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event) [ Time Frame: From date of randomization until date of first confirmed primary composite endpoint event, assessed up to 5.4 years ...
Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event) [ Time Frame: From date of randomization until date of first confirmed primary composite endpoint event, assessed up to 5.4 years ...
Sensipar (Cinacalcet Hydrochloride) Drug Safety Communication - FDA Suspends Pediatric Clinical Trials After Report Of Death AUDIENCE Health Professional, Endoc
BACKGROUND. The ultimate target of this project is to develop a biocompatible Ti-based metallic glass (MG) implant with modulated topography which potentially promotes the cellular response from initial attachment and migration to differentiation and production of new tissue without the need of exogenous growth factors. In order to achieve this goal four main scientific milestones are targeted: (i) Developing a novel Ti-based biocompatible MG with enhanced (micro)patterning kinetics. (ii) Defining appropriate routes to achieve material properties which function as an excellent stress-shielding material in daily use. (iii) Production and tuning of surface patterns with improved antimicrobial/osseointegrative properties. (iv) Investigation and understanding the mechanisms of cell adhesion, bactericidal adhesion and biocorrosion.. The Achilles heel of Ti-based MGs is the marginal drop in viscosities and relatively high strength within their supercooled liquid region. Hence, in addition to all the ...
View and buy high purity Cinacalcet hydrochloride from Tocris Bioscience. Allosteric Calcium-sensing receptor (CaSR) agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailable.
This study evaluated the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.
Cinacalcet therapy for achievement of the NKF/K-DOQITM clinical practice guidelines for bone and mineral metabolism in individuals under regular hemodialysis
Hypercalcemia of malignancy is the most common cause of hypercalcemia in hospitalized patients. It is associated with a poor prognosis, since it reflects an advanced cancer stage. Among all cancer in females, breast cancer is the most common malignancy, and it has the highest prevalence of hypercalcemia. Approximately 70% of patients with breast cancer have bone metastases and 10% of them will have hypercalcemia as a complication at some point in the disease. Herein, we report a 69-year-old female patient with metastatic breast cancer, who developed severe hypercalcemia in the course of her disease and was diagnosed with humoral hypercalcemia of malignancy (HHM). Intense hydration along with corticoisteroids and antiresorptive medication (calcitonin, bisphosphonates and denosumab) were administered to the patient. Despite the above treatment, serum calcium levels remain elevated and calcimimetic cinacalcet was added. Upon discontinuation of cinacalcet, calcium levels were raised and returned ...
Dr. Dehmel joins OxThera after serving as Executive Medical Director and Global Development Leader for Amgens calcimimetic franchise. He has extensive experience in the life science sector, having led Medical Affairs and Clinical Development teams responsible for drugs in Diabetes and End Stage Renal Disease. Bastian brings extensive experience in working with global regulatory agencies and was responsible for FDA and EMA approval of etelcalcetide, and more recently for the orphan pediatric drug approval of cinacalcet by EMA ...
Generic for mimpara (cinacalcet) is used for treating hyperparathyroidism. Order more than 10 tablets at our pharmacy and save your money.
Chronic renal failure is almost always associated with secondary uraemic hyperparathyroidism. Action should be taken as early as possible to avoid it or reduce its severity in patients with chronic kidney disease (CKD). Over the last decade, the most effective way of achieving this has been defined as therapy with active vitamin D derivatives. However, the so‐called non‐hypercalcaemic vitamin D derivatives, which are said to be superior, have not met our expectations so far. In contrast, calcimimetic agents, the new class of compounds that act specifically on the calcium‐sensing receptor, are very promising for the treatment and prevention of hyperparathyroidism. CKD is associated with disturbances in calcium, phosphate, and vitamin D metabolism that occur early in the course of renal disease. In most patients, these disturbances lead to secondary hyperparathyroidism and osteitis fibrosa or associated, more complex, skeletal lesions. Here, we focus on recent advances in the prevention ...
Paricalcitol allowed the achievement of target parathyroid hormone levels better than cinacalcet in patients with secondary hyperparathyroidism (SHPT), a complication of chronic kidney disease (CKD). Both a vitamin D receptor activator such as paricalcitol and a calcimimetic such as cinacalcet effectively treat SHPT, which is characterized by elevated serum levels of intact parathyroid hormone (iPTH). Elevated iPTH levels can lead to skeletal and cardiovascular complications.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
and expressly disclaims any duty to update information contained in this news release.. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us and our partners to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar ...
The calcium-sensing receptor (CASR) is the main calcium sensor in the maintenance of calcium metabolism. Mutations of the CASR, the G protein alpha 11 (GNA11) and the adaptor-related protein complex 2 sigma 1 subunit (AP2S1) genes can shift the set point for calcium sensing causing hyper- or hypo-calcemic disorders. Therapeutic concepts for these rare diseases range from general therapies of hyper- and hypo-calcemic conditions to more pathophysiology oriented approaches such as parathyroid hormone (PTH) substitution and allosteric CASR modulators. Cinacalcet is a calcimimetic that enhances receptor function and has gained approval for the treatment of hyperparathyroidism. Calcilytics in turn attenuate CASR activity and are currently under investigation for the treatment of various diseases. We conducted a literature search for reports about treatment of patients harboring inactivating or activating CASR, GNA11 or AP2S1 mutants and about in vitro effects of allosteric CASR modulators on mutated ...
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
CaSR signaling activity measured as the ratio between the level of phosphorylated and total p42/44 proteins. a: compared with the WT for both the Ca2+ concentra
In February, manufacturer Amgen announced that the FDA approved Parsabiv (etelcalcetide) for secondary hyperparathyroidism in patients with chronic kidney disease (CKD) on hemodialysis. Secondary hyperparathyroidism is a condition that lowers calcium levels, causing your parathyroid glands to overproduce the
Hypercalcemia of malignancy is the most common cause of hypercalcemia in hospitalized patients. It is associated with a poor prognosis, since it reflects an advanced cancer stage. Among all cancer in females, breast cancer is the most common malignancy, and it has the highest prevalence of hypercalcemia. Approximately 70% of patients with breast cancer have bone metastases and 10% of them will have hypercalcemia as a complication at some point in the disease. Herein, we report a 69-year-old female patient with metastatic breast cancer, who developed severe hypercalcemia in the course of her disease and was diagnosed with humoral hypercalcemia of malignancy (HHM). Intense hydration along with corticoisteroids and antiresorptive medication (calcitonin, bisphosphonates and denosumab) were administered to the patient. Despite the above treatment, serum calcium levels remain elevated and calcimimetic cinacalcet was added. Upon discontinuation of cinacalcet, calcium levels were raised and returned ...
SAN DIEGO, Nov. 15 -- Amgen (Nasdaq: AMGN), the worlds largest biotechnology company, announced results of phase 3 studies evaluating the efficacy and safety of cinacalcet HCl, a first-in-class oral calcimimetic, administered once daily for the treatment of secondary hyperparathyroidism (HPT) associated with chronic kidney disease (CKD). These results were presented at an American Society of Nephrology (ASN) sponsored symposium in San Diego.. Amgen recently received notification that the U.S. Food and Drug Administration (FDA) granted a priority review for cinacalcet HCl, a novel therapeutic that modulates the activity of the calcium-sensing receptor, the primary regulator of PTH secretion. Cinacalcet HCl is the first investigational agent to demonstrate simultaneous reductions in parathyroid hormone (PTH), calcium-phosphorus product, phosphorus and calcium levels to successfully control secondary HPT. Moreover, cinacalcet HCl may allow patients to achieve PTH and mineral targets in accordance ...
Looking for online definition of nutritional secondary hyperparathyroidism in the Medical Dictionary? nutritional secondary hyperparathyroidism explanation free. What is nutritional secondary hyperparathyroidism? Meaning of nutritional secondary hyperparathyroidism medical term. What does nutritional secondary hyperparathyroidism mean?
The drugs cinacalcet and etelcalcetide are allosteric modifiers of the calcium-sensing receptor.[14] They are classified as a calcimimetics, binding to the calcium-sensing receptor and decreasing parathyroid hormone release. Calcilytic drugs, which block CaSR, produce increased bone density in animal studies and have been researched for the treatment of osteoporosis. Unfortunately clinical trial results in humans have proved disappointing, with sustained changes in bone density not observed despite the drug being well tolerated.[15][16] More recent research has shown the CaSR receptor to be involved in numerous other conditions including Alzheimers disease, asthma and some forms of cancer,[17][18][19][19][20] and calcilytic drugs are being researched as potential treatments for these. Recently it has been shown that biomimetic bone like apatite inhibits formation of bone through endochondral ossification pathway via hyperstimulation of extracellular calcium sensing receptor[21]. ...
Secondary hyperparathyroidism is characterized by pronounced parathyroid gland hyperplasia resulting from end-organ resistance to parathyroid hormone (PTH). The consequent hypersecretion of PTH depresses calcium levels.
Secondary Hyperparathyroidism Pipeline Review, H1 2017, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P5
Generic for sensipar is used for treating overactive parathyroid gland. Order 30mg and 60m dosages at InternationalDrugMart and save up to $226.64
The objective of the study was to determine whether the use of cinacalcet in patients undergoing hemodialysis would reduce the rates of death and major cardiovascular events, including myocardial infarction, hospitalization for unstable angina, heart failure and peripheral vascular events, all of which were considered endpoints for the study.. The burden of hemodialysis treatment is considerable, and most patients take several prescription medications, often several times per day, Chertow said. Cinacalcet is not a perfect drug. It has been shown to be safe and the gastrointestinal side effects are not prohibitive, but when someone is taking 20 pills a day, it is difficult to justify the 21st unless it makes an important difference.. The trial, which was originally designed to last four years, was extended to nearly five and a half years in an attempt to reach the required number of endpoints. Between Aug. 22, 2006, and Jan. 31, 2008, researchers recruited 3,883 patients on hemodialysis with ...
"Calcium-sensing receptor and calcimimetic agents". Kidney International Supplements. 73: S52-8. doi:10.1046/j.1523-1755.1999. ... Nemeth EF, Shoback D (Jun 2013). "Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders". Best ...
Coburn JW, Elangovan L, Goodman WG, Frazaõ JM (Dec 1999). "Calcium-sensing receptor and calcimimetic agents". Kidney ... Nemeth EF, Shoback D (Jun 2013). "Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders". Best ...
2018). "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on ...
"Definition of calcimimetic", Medicine.net (on line). Last editorial review: 4/8/2004. William G. Goodman, "Calcimimetic agents ... A calcimimetic is a pharmaceutical drug that mimics the action of calcium on tissues, by allosteric activation of the calcium- ... Calcimimetic use can have side effects. Common side effects include: nausea and vomiting, hypocalcemia, and adynamic bone ... Cinacalcet was the first calcimimetic to be approved. Cinacalcet mimics calcium at the parathyroid hormone receptor. This ...
"Calcium-sensing receptor and calcimimetic agents". Kidney International Supplements. 73: S52-8. doi:10.1046/j.1523-1755.1999. ... Nemeth EF, Shoback D (Jun 2013). "Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders". Best ...
"Definition of calcimimetic", Medicine.net (on line). Last editorial review: 4/8/2004. William G. Goodman, "Calcimimetic agents ... A calcimimetic is a pharmaceutical drug that mimics the action of calcium on tissues, by allosteric activation of the calcium- ... Calcimimetic use can have side effects. Common side effects include: nausea and vomiting, hypocalcemia, and adynamic bone ... Cinacalcet was the first calcimimetic to be approved. Cinacalcet mimics calcium at the parathyroid hormone receptor. This ...
  • Sensipar/Mimpara is an oral calcimimetic agent approved for the treatment of secondary HPT in patients with CKD receiving dialysis. (drugs.com)
  • Sensipar/Mimpara is the first oral calcimimetic agent approved for the treatment of secondary HPT in CKD patients receiving dialysis. (drugs.com)
  • Cinacalcet hydrochloride (cinacalcet), an oral calcimimetic agent has been widely used for the management of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD). (bioportfolio.com)
  • On August 25, 2015 Amgen Inc. announced that it had submitted a new drug application with the United States Food and Drug Administration for a new calcimimetic, etelcalcetide (formerly velcalcetide), for the treatment of SHPT in chronic kidney disease (CKD) patients on hemodialysis. (wikipedia.org)
  • If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously. (amgen.com)
  • Etelcalcetide shall be the 1st calcimimetic agent that can be administered intravenously. (hitthebeach.net)
  • Etelcalcetide, a synthetic peptide calcimimetic, allosterically activates the calcium-sensing receptor (CaSR) on the parathyroid gland, resulting in decreased PTH secretion, and serum calcium and phosphorus levels in patients with secondary hyperparathyroidism on hemodialysis (Alexander 2015). (medicine.com)
  • Although etelcalcetide was associated with the largest reduction in PTH levels, side-effect profiles differed across the 3 calcimimetic agents, making it not possible to identify 1 preferred agent. (bvsalud.org)
  • 4 Sensipar ® (cinacalcet), the first FDA-approved calcimimetic, became an important treatment for patients with secondary HPT on dialysis based on its ability to reduce three important biochemical abnormalities (PTH, calcium, phosphorus). (chemdiv.com)
  • Secondary HPT is a serious condition and the proportion of patients unable to reach recommended secondary HPT lab targets has more than doubled in the last five years.4 Sensipar (cinacalcet), the first FDA-approved calcimimetic, became an important treatment for patients with secondary HPT on dialysis based on its ability to reduce three important biochemical abnormalities (PTH, calcium, phosphorus). (salesandmarketingnetwork.com)
  • Amgen, NPS Pharmaceuticals, and Brigham & Women's Hospital against various generic drug manufacturers in litigation on patents covering the calcimimetic Sensipar® for treating hyperparathyroid and carcinoma conditions. (fitzpatrickcella.com)
  • Calcimimetic Agents/ or (Calcimimetic* or amg073 or cinacalcet or "krn 1493" or krn1493 or mimpara or parareg or regpara or sensipar).mp. (biomedcentral.com)
  • William G. Goodman, "Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention" Nephrology Dialysis Transplantation (2002) 17: 204-207. (wikipedia.org)
  • The calcimimetic cinacalcet is used to treat secondary hyperparathyroidism in patients receiving dialysis, and asymptomatic hypocalcemia is often observed following its initiation. (bioportfolio.com)
  • The calcimimetic agent cinacalcet is effective for the management of secondary hyperparathyroidism (SHPT) in dialysis patients. (springermedizin.de)
  • The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. (springermedizin.de)
  • Cinacalcet, a calcimimetic agent, is effective in treating both primary and secondary hyperparathyroidism. (oup.com)
  • Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. (medecinesciences.org)
  • Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. (medecinesciences.org)
  • The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. (medecinesciences.org)
  • Acute effect of calcimimetic agent (CA) on hemodialysis (HD) patients with secondary hyperparathyroidism (2HPT). (medecinesciences.org)
  • Single doses of the calcimimetic AMG-073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. (medecinesciences.org)
  • Here, we focus on recent advances in the prevention and treatment of secondary hyperparathyroidism by vitamin D derivatives and by calcimimetic agents. (oup.com)
  • RATIONALE & OBJECTIVE: Comparative benefits and harms of calcimimetic agents used for the treatment of secondary hyperparathyroidism have not been well characterized. (bvsalud.org)
  • A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. (hdcn.com)
  • The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. (medecinesciences.org)
  • Cinacalcet is a calcimimetic drug that allos-terically activates the calcium-sensing receptor expressed on the surface of the chief cells of the parathyroid gland. (ectrx.org)
  • We report the results of two identical randomized, double-blind, placebo-controlled trials evaluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride. (nih.gov)
  • Another authorization by the European Commission (EC) was granted for Amgen's Parsabiv, a new calcimimetic agent administered to adult patients suffering from chronic kidney disease (CKD) who are undergoing hemodialysis. (mynewsdesk.com)
  • Amgen's Parsabiv is a new calcimimetic agent for treating sHPT in adult CKD patients on hemodialysis. (ckdnews.com)
  • Parsabiv is the first therapy approved for this condition in 12 years and the only calcimimetic that can be administered intravenously by the dialysis health care team three times a week at the end of the hemodialysis session. (chemdiv.com)
  • Conclusion: Calcimimetic treatment of patients with SHPT leads to significant improvements in biochemical parameters that observational studies have associated with increased mortality, cardiovascular risk, and osteitis fibrosa, but patient-based benefits have not yet been shown. (elsevier.com)
  • The potential role of calcimimetics as vasculotropic agents has been suggested since the discovery that calcium sensing receptors (CaSRs) are expressed in cardiovascular tissues. (figshare.com)
  • Calcimimetics are drug agents that mimic the action of calcium on tissues by activating the calcium-sensing receptor that is expressed in various human organ tissues, including the parathyroid gland, thereby decreasing PTH levels. (ckdnews.com)
  • PTH and possibly some of its analogues are promising therapeutic agents for the treatment of postmenopausal or senile osteoporosis, and calcimimetic agents, which activate the CaSR, have provided new approaches for PTH suppression. (mhmedical.com)
  • These agents, however, put the patient at risk for developing hypercalcemia and may not be efficient at resolving the hyperparathyroidism. (ahcmedia.com)
  • None of these agents, however, significantly lowers serum calcium or PTH levels. (nih.gov)
  • Parsabiv is the first approved calcimimetic drug that can be administered intravenously. (ckdnews.com)
  • The calcimimetic cinacalcet reduces both serum calcium and PTH levels and raises serum phosphorus. (nih.gov)
  • The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. (medecinesciences.org)
  • Szczech LA. The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials. (medscape.com)
  • Traditional agents used to treat hyperparathyroidism typically include vitamin D sterols and calcium-containing phosphate binders. (ahcmedia.com)
  • Heath H, Sanguinetti E, Oglesby S, Marriott T. Inhibition of parathyroid hormone secretion in vivo by NPS 5-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor. (medecinesciences.org)
  • Calcimimetic: A drug in a class of orally active, small molecules that decrease the secretion of parathyroid hormone (PTH) by activating calcium receptors. (drugline.org)
  • A calcimimetic is a pharmaceutical drug that mimics the action of calcium on tissues, by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. (wikipedia.org)
  • NPS R-568 : a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. (medecinesciences.org)
  • Methods: MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and conference proceedings were searched for randomized controlled trials evaluating any calcimimetic against placebo or another agent in predialysis or dialysis patients with chronic kidney disease. (elsevier.com)
  • Results: Eight trials (1,429 patients) were identified that compared a calcimimetic agent plus standard therapy with placebo plus standard therapy. (elsevier.com)
  • 95% CI, -10.25 to -5.54) were significantly lower with calcimimetic therapy compared with placebo. (elsevier.com)
  • Compared with placebo, calcimimetic agents had higher odds of achieving target PTH levels with high or moderate certainty. (bvsalud.org)
  • These agents are potentially active in the urinary tract due to its elimination in an unaltered form by the renal route. (biomedsearch.com)
  • The ability to provide my patients with an intravenous calcimimetic and help ensure they receive the therapy they need is a tremendous milestone in the management of this frequently undertreated chronic progressive disease. (chemdiv.com)
  • SETTING & STUDY POPULATION: Adults with chronic kidney disease enrolled in a clinical trial of a calcimetic agent. (bvsalud.org)
  • Differences in risk for mortality, cardiovascular end points, or fractures across calcimimetic agents could not be discerned with sufficient certainty. (bvsalud.org)
  • Treatment in the initial stage consists of a low-protein diet with restricted sodium intake and administration of hypotensive agents in the case of hypertension and of anabolic hormones, cardiac stimulants, and other drugs. (thefreedictionary.com)
  • An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism. (clinicaltrials.gov)
  • A highly efficient and convenient procedure for the enantioselective synthesis of ( S )-Rivastigmine, a cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease, is accomplished by the treatment of versatile, readily accessible ( S )-(-)-2-methyl-2-propanesulfinamide with 3-hydroxyacetophenone. (scirp.org)
  • In contrast, calcimimetic agents, the new class of compounds that act specifically on the calcium‐sensing receptor, are very promising for the treatment and prevention of hyperparathyroidism. (oup.com)
  • We sought to compare the effectiveness of 3 calcimimetic agents using published data. (bvsalud.org)
  • They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. (nih.gov)
  • Cinacalcet, a calcimimetic agent that activates the calcium-sensing receptors in parathyroid glands, is a therapeutic option. (ectrx.org)
  • CONCLUSIONS: Evidence of the benefits of calcimimetic therapy is limited to short-term assessment of a putative surrogate outcome (serum PTH). (bvsalud.org)
  • Inhaled methods such as exsanguination or pithing to ensure agents have greater application for pigs weighing 70 death. (arcflorida.com)
  • La combinación más efectiva fue el empleo de partículas de E. grandis, combinadas indistintamente con los cementos CPC40 o ARI50, adicionados con 3% de cloruro de calcio Resumen en inglés The most part of residues generated during wood mechanic processing remains unexplored for construction material non-structural compounds production. (worldwidescience.org)
  • In contrast, calcimimetic agents, the new class of compounds that act specifically on the calcium‐sensing. (oup.com)
  • Overall, these findings provide new insight on the mechanisms of action of the calcimimetic R-568 in modulating vascular tone both in physiological and pathological conditions such as hypertension. (figshare.com)
  • This phenomenon is termed ''cell adhesion-mediated drug resistance'' (CAM-DR) and it is thought to be one of the major mechanisms by which MM cells escape the cytotoxic effects of therapeutic agents. (eurekaselect.com)
  • Sanofi-Aventis and Bristol-Myers Squibb against various generic drug manufacturers in litigation and several reexamination proceedings on patents covering Plavix®, a leading anti-thrombotic agent. (fitzpatrickcella.com)
  • SODIUM HYDROXIDE and potassium hydroxide are the most widely used caustic agents in industry. (nih.gov)
  • Cinacalcet is the first in a class of calcimimetic agents that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. (ahcmedia.com)
  • Agents that have a strengthening effect on the heart or that can increase cardiac output. (nih.gov)
  • Calcimimetic R-568 vasodilatory effect on mesenteric vascular beds from normotensive (WKY) and spontaneously hypertensive (SHR) rats. (figshare.com)
  • A cooling sensation agent composition with a prolonged cool sensation effect is provided comprising at least one compound selected from the group consisting of. (patents.com)

No images available that match "calcimimetic agents"